Free Shipping on purchases over €100

Neoretin Depigmentation Protocol, Discrom Control Ultra Emulsion 50Ml + Biretix Oil Control 30Ml

Neoretin Depigmenting Protocol, Discrom Control Ultra Emulsion, 30Ml + Biretix Oil Control, 30Ml

Neoretin Depigmenting Protocol, Discrom Control Ultra Emulsion, 30Ml + Biretix Oil Control, 30Ml Intensive depigmenting emulsion with high concentrations of depigmenting and anti-pollution active ingredients. Includes BIRETIX OIL CONTROL SOLUTION gift samples, a facial skin activating solution with triple mattifying, sebum regulating and pore minimising action.

SKU: NE8436574364910
-26%
48.80
€65.90

Pharmaceutical Care

Safe medication sales

Secure shipping

INFO AND TECHNICAL SPECIFICATIONS

Neoretin Depigmenting Protocol, Discrom Control Ultra Emulsion 30Ml + Biretix Oil Control 30Ml Combines depigmenting and retexturising technologies to provide rapidly visible results. Formulated with RetinSphere® Technology, with a high concentration of retinoids, it provides intense epidermal renewal and smoother skin. Niacinamide and tranexamic acid help block the formation of blemishes by acting on the different mechanisms of melanin synthesis.

EDAFENCE® protects against pollution, one of the main causes of blemishes, and other factors caused by environmental stress. Its anhydrous texture facilitates the application of the product, leaving an imperceptible finish and a dry feel. Tested under dermatological control. BIRETIX OIL CONTROL SOLUTION thanks to the combination of AHAs in its formula, stimulates the renewal of the epidermis for a luminous and uniform skin, and helps to reduce post-inflammatory hyperpigmentation. Rose extract provides gentle and soothing care, even on sensitised oily skin.

Tecnical specifications card

Pharmaceutical advice

You can now consult our team with any questions you may have. We remind you that our chatbot is also available for simpler queries.

Ask us
Newsletter

Don’t miss anything

Stay up to date with the latest advances in health, discounts, and pharmaceutical news.